Chasse_Patate schreef op 19 mei 2021 07:56:
“We continue to achieve very strong early commercial success as we execute the launch strategy for BARHEMSYS® and BYFAVO™ in the US and are delighted to welcome Deb to our high-performing team,” said Mike Bolinder, Chief Executive Officer at Acacia Pharma.
Er staat geen strong, maar very strong.
Voorlopig geen vuiltje aan de lucht is dan mijn conclusie.